ADC Collaborations

There are more than 15 collaborator ADC programs in clinical development using our technology.

Learn more

ADC Technology

Our pipeline of empowered antibody-based product candidates is based primarily on our ADC technology.

Learn more

A diversified product pipeline

We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Our robust pipeline of empowered antibody-based therapies is designed to address significant unmet medical needs.

Program Therapeutic Area Preclinical Phase 1 Phase 2 Pivotal/ Phase 3 Approved
ADCETRIS® (brentuximab vedotin)
Relapsed Hodgkin lymphoma (HL)
Relapsed systemic anaplastic large cell lymphoma
Brentuximab Vedotin
AETHERA: Post-transplant HL relapse prevention
ALCANZA: CD30+ cutaneous T-cell lymphoma
ECHELON-1: Frontline HL
(+ chemotherapy)
ECHELON-2: Frontline CD30+ mature T-cell lymphomas (+ chemo)
Frontline HL in patients 60+ (+/− other agents)
Frontline CD30+ DLBCL
(+ RCHP)
CD30+ non-lymphoma malignancies
CD30+ DLBCL (Rituxan + bendamustine +/− BV) (Planned)
Second-line HL
(+ bendamustine)
DLBCL (R-ICE +/− SGN-CD19A) (Planned)
AML (single agent and combinations)
Breast cancer
NHL, renal cell carcinoma
Solid tumors
Bladder cancer
Solid tumors

*Co-development program with Agensys, an affiliate of Astellas
**Non-fucosylated antibody utlizing a novel immuno-oncology technology

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave